A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder
Open accessThe DOI matches its Crossref record; 123 of the 135 references it cites were found in a registry or an index; 84 of the 164 sources its claims cite were checked for support.
Abstract
Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the current treatment landscape and novel strategies for both alcohol withdrawal syndrome and AUD. Promising results, including the use of psychedelics alongside psychotherapy, noninvasive neural-circuit-based interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, have emerged from recent studies. While these advancements show potential, further research is crucial for a comprehensive understanding of their effectiveness. The clear shortage of approved medications and other treatment modalities underscores the pressing need for ongoing research. © 2024 by the authors.
Overview
CoChat Summary
## TL;DR
This narrative review surveys current and emerging treatments for alcohol withdrawal syndrome (AWS) and alcohol use disorder (AUD), emphasizing that benzodiazepines remain first-line for AWS while only three medications are FDA-approved for AUD: disulfiram, acamprosate, and naltrexone. It highlights promising but still emerging options, especially psychedelics with psychotherapy, noninvasive neural-circuit interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, while stressing that more clinical research is needed.
## Key findings
- AUD is described as a major public health problem, contributing to over 140,000 annual deaths, over 200 related diseases and health conditions globally, and 5.1% of the global disease burden; the paper also states that only 7% of U.S. adults with AUD receive adequate treatment and only 16% of those treated achieve abstinence.
- For AWS, benzodiazepines are the gold standard/first-line treatment; in one RCT of 198 patients, phenobarbital reduced ICU admissions from 25.0% to 8.0% versus placebo, and a meta-analysis of 12 studies/1,934 patients found no difference between phenobarbital and benzodiazepines on intubation, seizures, or hospital/ICU length of stay.
- For AUD, the paper reports FDA-approved options as disulfiram, acamprosate, and naltrexone; a meta-analysis of 53 studies found the number needed to treat for naltrexone was 12 to prevent return to heavy drinking, and a meta-analysis of 24 RCTs (6,915 participants) found acamprosate reduced the risk of any drinking and increased cumulative abstinence.
- Several emerging treatments showed promising signals: psilocybin plus psychotherapy produced a twofold reduction in heavy drinking with NNT 4.5 over 32 weeks; semaglutide case series reported a mean AUDIT score decrease of 9.5 points (p < 0.001) in 6 patients; and exenatide in an RCT of 127 participants did not reduce heavy drinking days overall but did reduce cue reactivity, with benefit in the subgroup with BMI > 30 kg/m².
## Methods
- Narrative review based on an electronic literature search of PubMed, Google Scholar, Cochrane Library, and ClinicalTrials.gov.
- Included clinical and animal trials, plus relevant systematic reviews, meta-analyses, and case reports published between 1 January 2013 and 1 January 2024; excluded editorials, expert opinions, and meeting abstracts.
- Search terms covered alcohol, alcohol use disorder, alcohol withdrawal syndrome, alcohol dependence, alcohol consumption, relapse, anti-craving, and treatment-related terms; the review also provides brief historical/background context for each modality.
## Limitations
- The paper explicitly notes that for several interventions, data are scarce or no recent clinical trials were identified (for example, ketamine for AWS, antipsychotics for AWS, GHB for AWS, CBT in recent AUD studies, PF-5190457, and others), so evidence is uneven across treatments.
- The review states that further research is crucial and that many findings are promising but not yet definitive, especially for emerging modalities such as psychedelics, neural-circuit interventions, PDE-4 inhibitors, and GLP-1 agonists.
- Evident from the text: this is a narrative review, not a systematic review or meta-analysis of its own, so the synthesis depends on heterogeneous prior studies and does not report a single pooled effect estimate across the full topic.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
84 Valid · 2 Not valid · 76 Not checked · 16 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“There is no specific preference for a particular benzodiazepine in the existing literature, highlighting the need for personalized medication selection, particularly considering factors like liver dysfunction [10].”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 3. Results > 3.1. Benzodiazepines for AWS
What the sources say
- Supportedcites [10] Amato L. Minozzi S. Vecchi S. Davoli M. Benzodiazepines for alcohol withdrawal Cochrane Database Syst. Rev. 2010 3 CD005063 10.1002/14651858.CD005063.pub3 20238336 PMC12414628 source
The Discussion (page not provided) says there is no strong evidence that particular benzodiazepines are more effective than others for alcohol withdrawal, which supports the attributed claim. The sentence’s recommendation to personalize selection, including for liver dysfunction, is the citing authors’ inference rather than a finding established by this passage. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Benzodiazepines are currently the first-line treatment for AWS [10].”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 1. Introduction
What the sources say
- Supportedcites [10] Amato L. Minozzi S. Vecchi S. Davoli M. Benzodiazepines for alcohol withdrawal Cochrane Database Syst. Rev. 2010 3 CD005063 10.1002/14651858.CD005063.pub3 20238336 PMC12414628 source
The Discussion (page not provided) explicitly refers to benzodiazepines’ “current status as first-line treatment for alcohol withdrawal syndrome.” The claim describes that status, not a claim that they are superior to every alternative. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In another retrospective study of 30 patients receiving ketamine adjunctively with a lorazepam infusion for severe alcohol withdrawal, significant decreases in lorazepam infusion rates were observed at 24 h after ketamine initiation.”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 3. Results > 3.2. Medications Other than Benzodiazepines for Alcohol Withdrawal Syndrome
What the sources say
- Supportedcites [25] Shah P. McDowell M. Ebisu R. Hanif T. Toerne T. Adjunctive Use of Ketamine for Benzodiazepine-Resistant Severe Alcohol Withdrawal: A Retrospective Evaluation J. Med. Toxicol. 2018 14 229 236 10.1007/s13181-018-0662-8 29748926 PMC6097970 source
The Abstract Methods describe a retrospective review of patients receiving ketamine adjunctively with a lorazepam infusion for severe alcohol withdrawal. The Abstract Results report 30 patients and a significant decrease in lorazepam infusion rates from baseline at 24 hours after ketamine initiation. The Results > Outcomes section cautions that the study could not determine whether ketamine caused the decrease; the citing sentence reports the observed decrease, not causation. (LLM, conf=0.95)
plainstates a causen = 30- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The study found that high-dose gabapentin was statistically superior but clinically similar to lorazepam in reducing alcohol withdrawal severity.”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 3. Results > 3.2. Medications Other than Benzodiazepines for Alcohol Withdrawal Syndrome
What the sources say
- Supportedcites [31] Myrick H. Malcolm R. Randall P.K. Boyle E. Anton R.F. Becker H.C. Randall C.L. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal Alcohol. Clin. Exp. Res. 2009 33 1582 1588 10.1111/j.1530-0277.2009.00986.x 19485969 PMC2769515 source
The Abstract Methods section reports that 100 people seeking outpatient treatment for alcohol withdrawal were randomized to double-blind gabapentin or lorazepam treatment. The Abstract Results section states that high-dose gabapentin was statistically superior but clinically similar to lorazepam in reducing withdrawal severity, measured by CIWA-Ar scores (p=0.009). No page numbers are available in our copy. (LLM, conf=0.95)
plainstates a causen = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The study measured the need for diazepam during withdrawal and found that 32.0% of patients on baclofen 60 mg/day required additional diazepam, compared to 72.0% on the placebo.”
§ A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder > 3. Results > 3.2. Medications Other than Benzodiazepines for Alcohol Withdrawal Syndrome
What the sources say
- Partly supportedcites [16] Crunelle C.L. Jegham S. Vanderbruggen N. Matthys F. Baclofen during alcohol detoxification reduces the need for additional diazepam: A randomized placebo-controlled trial Alcohol Alcohol. 2023 58 565 569 10.1093/alcalc/agad050 37526038 sourceExperimental — accuracy not yet measured
The Results report that 8 of 25 patients (32.0%) receiving baclofen 60 mg/day needed diazepam, compared with 13 of 18 (72.2%) receiving placebo. The claim matches the baclofen figure but gives the placebo figure as 72.0%, rather than the 72.2% reported in the Results. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
83 more claims · 46 with their cited sources checked
Create a free account to see all 178 claims and to verify the 6 references still open.
- It may state two separate claims as one. 76
- The quote only partly states this claim. 5
- Probably not a substantial claim. 15
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 1×
“Despite being a significant public health concern, AUD is notably undertreated, with only 7% of adults in the US receiving adequate treatment for the disorder [5].”
BackgroundDysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
Goldstein, R. Z., & Volkow, N. D. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3119 · Cited by 2,749 · cited 1×
“Furthermore, the ventral PFC network, encompassing the medial PFC, orbitofrontal cortex, insular cortex, and ventral anterior cingulate cortex, influences emotional processing and limbic arousal in addiction [105].”
BackgroundNeurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008 · cited 1×
“Animal models have shown that both ethanol intake and anticipation prompt dopamine release in the NAc, impacting the mesocorticolimbic system associated with craving, reward, and behavioral control [111].”
BackgroundStrafella, A. P., Paus, T., Barrett, J., & Dagher, A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-j0003.2001 · Cited by 1,058
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 2×
“A large-scale meta-analysis, comprising 27 RCTs, found that acamprosate was effective in prolonging abstinence but did not reduce rates of binge drinking [51].”
BackgroundObesity and addiction: Neurobiological overlaps
Volkow, N. D., Wang, G. ‐., Tomasi, D., & Baler, R. D. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01031.x · Cited by 800 · cited 1×
“This is believed to be associated with lower dopamine receptor levels in the striatum, impacting frontal brain regions and causing imbalances in motivation, inhibition, and stress reactivity [94].”
BackgroundOral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711 · cited 1×
“Furthermore, the psilocybin group had three times higher chances of having no heavy drinking days and fewer alcohol-related adverse consequences compared to the diphenhydramine group [78].”
BackgroundThe impact of brief alcohol interventions in primary healthcare: a systematic review of reviews
O'Donnell, A., Anderson, P., Newbury-Birch, D., Schulte, B., Schmidt, C., Reimer, J., & Kaner, E. (2014) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt170 · Cited by 613 · cited 1×
“These interventions typically take 5 to 20 min and are recommended for all patients with risky alcohol use [116].”
BackgroundDopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., Swanson, J. M., & Telang, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1575 · Cited by 605
Schacht, J. P., Anton, R. F., & Myrick, H. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00464.x · Cited by 583 · cited 1×
“Neuroimaging studies consistently demonstrate that exposure to alcohol cues increases activation in the NAc and striatum, which is correlated with subjective alcohol craving [113].”
BackgroundLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · cited 1×
“However, this effect did not remain statistically significant beyond the 12-month mark [75].”
BackgroundDiagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580 · cited 1×
“There is a debate about whether disulfiram should be employed as a primary treatment for AUD or if its use should be reserved as an adjunct for maintaining abstinence [53].”
BackgroundManagement of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Cork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478
Alcoholics Anonymous and other 12-step programs for alcohol use disorder
Kelly, J. F., Humphreys, K., & Ferri, M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012880.pub2 · Cited by 462 · cited 1×
“Findings demonstrated that manualized AA/TSF significantly improved continuous abstinence rates at 12 months compared to CBT. Non-manualized AA/TSF also showed similar performance to other interventions in terms of abstinence rates and drinking intensity at various follow-up periods [124].”
BackgroundMayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434 · cited 1×
“Another option is a symptom-triggered regimen, where the CIWA-Ar scale is utilized to monitor symptoms, and medications such as diazepam, lorazepam, or chlordiazepoxide are administered as required [12,13].”
MethodAcamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Jonas, D. E., Garbutt, J. C., Amick, H. R., Brown, J. M., Brownley, K. A., Council, C. L., Viera, A. J., Wilkins, T. M., Schwartz, C. J., Richmond, E. M., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00544 · Cited by 387
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385 · cited 1×
“Over the past decade, it has been investigated as a potential treatment for AUD [23]; however, studies investigating ketamine for AWS are limited.”
BackgroundGabapentin misuse, abuse and diversion: A systematic review
Smith, R. V., Havens, J. R., & Walsh, S. L. (2016) · Addiction · doi:10.1111/add.13324 · Cited by 378 · cited 1×
“However, it is crucial to consider potential side effects and the risk of misuse, particularly in patients with opioid use disorder [69].”
BackgroundReus, V. I., Fochtmann, L. J., Bukstein, O., Eyler, A. E., Hilty, D. M., Horvitz-Lennon, M., Mahoney, J., Pasic, J., Weaver, M., Wills, C. D., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.1750101 · Cited by 372 · cited 2×
“The practice guidelines of the American Psychiatric Association (APA) recommends pharmacotherapy in conjunction with psychosocial interventions for patients with moderate or severe AUD [9].”
BackgroundMethodDisulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347 · cited 1×
“In a meta-analysis of 22 studies, disulfiram demonstrated a higher success rate in promoting abstinence compared to placebo in open-label trials [52].”
MethodMagill, M., Ray, L., Kiluk, B., Hoadley, A., Bernstein, M., Tonigan, J. S., & Carroll, K. (2019) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000447 · Cited by 315 · cited 1×
“However, CBT effects compared to specific therapy (motivational interviewing, contingency management) were consistently non-significant across outcomes and follow-up times [120].”
BackgroundKlausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262 · cited 1×
“Notably, a subgroup of obese patients with a BMI over 30 kg/m 2 showed reduced heavy drinking and total alcohol intake, with primarily gastrointestinal side effects [104].”
BackgroundDaeppen, J.-B., Gache, P., Landry, U., Sekera, E., Schweizer, V., Gloor, S., & Yersin, B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1117 · Cited by 258
Myrick, H., Anton, R. F., Li, X., Henderson, S., Randall, P. K., & Voronin, K. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.466 · Cited by 258 · cited 1×
“Furthermore, both medications, whether administered alone or in combination, decreased activation of the ventral striatum in response to alcohol cues [71].”
BackgroundBenzodiazepines for alcohol withdrawal
Amato, L., Minozzi, S., Vecchi, S., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005063.pub3 · Cited by 245
Mitchell, J. M., O’Neil, J. P., Janabi, M., Marks, S. M., Jagust, W. J., & Fields, H. L. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002902 · Cited by 237 · cited 1×
“It exerts its effects through mu-opioid receptor antagonism, reducing cravings, the reinforcing effects of alcohol, and binge drinking [50].”
BackgroundChuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214 · cited 1×
“The research suggested that semaglutide influenced GABAergic synaptic transmission in brain areas associated with alcohol-related behaviors [101].”
BackgroundThe glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207 · cited 1×
“Additionally, Ex4 decreased alcohol-seeking behavior [100].”
Benzodiazepines for alcohol withdrawal
Ntais, C., Pakos, E., Kyzas, P., & Ioannidis, J. P. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005063.pub2 · Cited by 206
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal
Myrick, H., Malcolm, R., Randall, P. K., Boyle, E., Anton, R. F., Becker, H. C., & Randall, C. L. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00986.x · Cited by 201 · cited 1×
“Post-treatment, gabapentin-treated participants had a lower probability of drinking during the follow-up period and also exhibited less craving, anxiety, and sedation compared to lorazepam-treated participants [31].”
ResultAnton, R. F., Latham, P., Voronin, K., Book, S., Hoffman, M., Prisciandaro, J., & Bristol, E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0249 · Cited by 186 · cited 1×
“The study suggests that gabapentin may be more effective, especially in individuals with a history of high alcohol withdrawal symptoms [66].”
BackgroundDakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070684 · Cited by 183
Grabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., Hardy, L., Warren, F., Bloomfield, M., Borissova, A., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030277 · Cited by 175
Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses
Leone, M. A., Vigna-Taglianti, F., Avanzi, G., Brambilla, R., & Faggiano, F. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006266.pub2 · Cited by 163
Rosenson, J., Clements, C., Simon, B., Vieaux, J., Graffman, S., Vahidnia, F., Cisse, B., Lam, J., & Alter, H. (2013) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.07.056 · Cited by 162 · cited 1×
“%) compared to the placebo group [20].”
Suchankova, P., Yan, J., Schwandt, M. L., Stangl, B. L., Caparelli, E. C., Momenan, R., Jerlhag, E., Engel, J. A., Hodgkinson, C. A., Egli, M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.68 · Cited by 146 · cited 1×
“Furthermore, this genotype exhibited an elevated blood-oxygen-level dependent response in the right globus pallidus when participants were notified of a high monetary reward [97].”
BackgroundZangen, A., & Hyodo, K. (2002) · NeuroReport · doi:10.1097/00001756-200212200-00005 · Cited by 145 · cited 1×
“…influential studies demonstrated a causal relationship between the application of transcranial magnetic stimulation (TMS) on the prefrontal cortex and dopamine binding in the caudate nucleus, leading to an increase in extracellular dopamine and glutamate in the ventral striatum by TMS [106,107].”
BackgroundLee, M. R., Tapocik, J. D., Ghareeb, M., Schwandt, M. L., Dias, A. A., Le, A. N., Cobbina, E., Farinelli, L. A., Bouhlal, S., Farokhnia, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0064-y · Cited by 129 · cited 1×
“Furthermore, when used in conjunction with alcohol, PF-5190457 proved safe and well tolerated, showing no adverse interactions between the drug and alcohol [93].”
BackgroundPeyote in the Treatment of Alcoholism Among American Indians
ALBAUGH, B. J., & ANDERSON, P. O. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.11.1247 · Cited by 128 · cited 1×
“The study claimed that, for many American Indians, a single peyote meeting served as a pivotal turning point [80].”
BackgroundBruhn, J. G., Smet, P. A. G. M. D., El-Seedi, H. R., & Beck, O. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08701-9 · Cited by 126
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124 · cited 1×
“The findings of this study suggest a potential positive association between mescaline use and the alleviation of various mental health symptoms [81].”
BackgroundBlednov, Y. A., & Adron Harris, R. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008584 · Cited by 123 · cited 1×
“Acamprosate acts as an NMDA receptor antagonist and modulates mGluR5 receptors [54].”
BackgroundA meta-analysis of the efficacy of gabapentin for treating alcohol use disorder
Kranzler, H. R., Feinn, R., Morris, P., & Hartwell, E. E. (2019) · Addiction · doi:10.1111/add.14655 · Cited by 121
Ray, L. A., Bujarski, S., Shoptaw, S., Roche, D. J., Heinzerling, K., & Miotto, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.10 · Cited by 118
Harel, M., Perini, I., Kämpe, R., Alyagon, U., Shalev, H., Besser, I., Sommer, W. H., Heilig, M., & Zangen, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.11.020 · Cited by 115
Preaddiction—A Missing Concept for Treating Substance Use Disorders
McLellan, A. T., Koob, G. F., & Volkow, N. D. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.1652 · Cited by 112 · cited 1×
“The ongoing discourse surrounding the integration of the concept of ‘preaddiction’ [128] offers a potential paradigm shift, suggesting a potential alternative to the mild or moderate substance use disorder criteria in DSM-5-TR.”
BackgroundBarnett, N. P., Celio, M. A., Tidey, J. W., Murphy, J. G., Colby, S. M., & Swift, R. M. (2017) · Addiction · doi:10.1111/add.13767 · Cited by 111 · cited 1×
“[122].”
Alcohol withdrawal syndromes: A review of pathophysiology, clinical presentation, and treatment
Turner, R. C., Lichstein, P. R., Peden, J. G., Busher, J. T., & Waivers, L. E. (1989) · Journal of General Internal Medicine · doi:10.1007/bf02599697 · Cited by 108 · cited 1×
“In the absence of alcohol, this leads to an increased stimulation of glutamate, ultimately In the absence of alcohol, this leads to an increased stimulation of glutamate, ultimately resulting in a state of neural excitability [7]. resulting in a state of neural excitability [7].”
BackgroundRole of α 2 -Agonists in the Treatment of Acute Alcohol Withdrawal
Muzyk, A. J., Fowler, J. A., Norwood, D. K., & Chilipko, A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p575 · Cited by 107 · cited 1×
“Importantly, since it does not activate GABA or opioid receptors, there is no respiratory compromise [35].”
BackgroundFan, A. Z., Chou, S. P., Zhang, H., Jung, J., & Grant, B. F. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14192 · Cited by 104
Gabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104
Baclofen for alcohol withdrawal
Liu, J., & Wang, L.-N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008502.pub5 · Cited by 102
Registered clinical studies investigating psychedelic drugs for psychiatric disorders
Siegel, A. N., Meshkat, S., Benitah, K., Lipsitz, O., Gill, H., Lui, L. M. W., Teopiz, K. M., McIntyre, R. S., & Rosenblat, J. D. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.019 · Cited by 97
Kearney-Ramos, T. E., Dowdle, L. T., Lench, D. H., Mithoefer, O. J., Devries, W. H., George, M. S., Anton, R. F., & Hanlon, C. A. (2018) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.03.016 · Cited by 97
Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital
Hecksel, K. A., Bostwick, J. M., Jaeger, T. M., & Cha, S. S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.274 · Cited by 97 · cited 1×
“However, benzodiazepines have adverse effects such as sedation, falls, aspiration, and respiratory depression [11].”
BackgroundWium‐Andersen, I. K., Wium‐Andersen, M. K., Fink‐Jensen, A., Rungby, J., Jørgensen, M. B., & Osler, M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13776 · Cited by 93 · cited 1×
“The findings revealed that initiating GLP-1 treatment was linked to a significantly lower risk of alcohol-related events compared to initiating DPP4 treatment during the first three months of follow-up [103].”
ResultFalk, D. E., Ryan, M. L., Fertig, J. B., Devine, E. G., Cruz, R., Brown, E. S., Burns, H., Salloum, I. M., Newport, D. J., Mendelson, J., et al. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13917 · Cited by 89 · cited 1×
“Additionally, no clinical benefits were observed for various drinking measures, alcohol craving, alcohol-related consequences, sleep problems, smoking, and depression/anxiety symptoms [67].”
BackgroundPrevention of alcohol withdrawal seizures with carbamazepine and valproic acid
Hillbom, M., Tokola, R., Kuusela, V., Kärkkäinen, P., Källi-Lemma, L., Pilke, A., & Kaste, M. (1989) · Alcohol · doi:10.1016/0741-8329(89)90022-0 · Cited by 81 · cited 1×
“However, these studies also concluded that the adverse effects associated with valproate use may outweigh the benefits [32,33].”
BackgroundGastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats
Davis, J. F., Schurdak, J. D., Magrisso, I. J., Mul, J. D., Grayson, B. E., Pfluger, P. T., Tschöp, M. H., Seeley, R. J., & Benoit, S. C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.01.035 · Cited by 81 · cited 1×
“Ghrelin is primarily recognized for its function in regulating appetite through the hypothalamic arcuate nucleus [89].”
BackgroundGamma hydroxybutyric acid (ghb) for the treatment of alcohol dependence: A review
Caputo, F., Vignoli, T., Maremmani, I., Bernardi, M., & Zoli, G. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6061917 · Cited by 73 · cited 1×
“It affects the GABA system both directly by acting as a partial agonist for GABA-B receptors, and indirectly by leading to the production of GABA from GHB [44].”
BackgroundBhattacharya, S. K., Andrews, K., Beveridge, R., Cameron, K. O., Chen, C., Dunn, M., Fernando, D., Gao, H., Hepworth, D., Jackson, V. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400473x · Cited by 73 · cited 1×
“PF-5190457, an inverse agonist for the ghrelin receptor discovered by Pfizer in the mid-2010s as a clinical candidate for diabetes, effectively suppresses GHS-R1a activity, both at its baseline function and in response to ghrelin [91].”
BackgroundBaclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub2 · Cited by 73 · cited 1×
“Overall, the review suggests that the use of baclofen as a first-line treatment for AUDs remains uncertain due to the lack of conclusive evidence and heterogeneity among studies [57].”
BackgroundVallöf, D., Kalafateli, A. L., & Jerlhag, E. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00923-1 · Cited by 72
Garbutt, J. C., Kampov-Polevoy, A. B., Pedersen, C., Stansbury, M., Jordan, R., Willing, L., & Gallop, R. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01055-w · Cited by 68 · cited 1×
“Notably, higher doses were less well tolerated in female participants [56].”
BackgroundPsilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Meinhardt, M. W., Güngör, C., Skorodumov, I., Mertens, L. J., & Spanagel, R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0694-z · Cited by 65 · cited 2×
“However, in a recent study with rats aimed at investigating the effects of psilocybin/LSD on the alcohol deprivation effect, neither of the two LSD doses used (0.08 and 0.32 mg/kg) had any impact on alcohol relapse in animal models [77].”
BackgroundInfluentialBach, P., Luderer, M., Müller, U. J., Jakobs, M., Baldermann, J. C., Voges, J., Kiening, K., Lux, A., Visser-Vandewalle, V., the DeBraSTRA study group, et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02337-1 · Cited by 65
Preclinical and clinical evidence for suppression of alcohol intake by apremilast
Grigsby, K. B., Mangieri, R. A., Roberts, A. J., Lopez, M. F., Firsick, E. J., Townsley, K. G., Beneze, A., Bess, J., Eisenstein, T. K., Meissler, J. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci159103 · Cited by 64 · cited 1×
“Additionally, apremilast exhibited a significant reduction in drinking, surpassing the efficacy of existing FDA-approved treatments for AUD, such as acamprosate and naltrexone [88].”
BackgroundThe neurological effects of ghrelin in brain diseases: Beyond metabolic functions
Jiao, Q., Du, X., Li, Y., Gong, B., Shi, L., Tang, T., & Jiang, H. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.010 · Cited by 62 · cited 1×
“Additionally, ghrelin has anti-inflammatory effects and has been shown to inhibit the release of pro-inflammatory cytokines [92].”
BackgroundSodium valproate in the treatment of the alcohol withdrawal syndrome
Lambie, D. G., Johnson, R. H., Vijayasenan, M. E., & Whiteside, E. A. (1980) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048678009159381 · Cited by 59 · cited 1×
“However, these studies also concluded that the adverse effects associated with valproate use may outweigh the benefits [32,33].”
BackgroundRichards, J. R., Dorand, M. F., Royal, K., Mnajjed, L., Paszkowiak, M., & Simmons, W. K. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23m15068 · Cited by 59 · cited 1×
“The results showed that all six patients experienced a significant reduction in AUD symptomatology, as evidenced by an improvement in AUDIT scores (mean decrease of 9.5 points, p 0.001) following semaglutide therapy [102].”
ResultInfluentialHarder, V. S., Musau, A. M., Musyimi, C. W., Ndetei, D. M., & Mutiso, V. N. (2020) · Addiction · doi:10.1111/add.14903 · Cited by 58 · cited 1×
“Secondary outcomes indicated no significant difference between in-person and mobile MI at 1 month, while results at 6 months were inconclusive [119].”
McCalley, D. M., Kaur, N., Wolf, J. P., Contreras, I. E., Book, S. W., Smith, J. P., & Hanlon, C. A. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2022.03.002 · Cited by 56 · cited 1×
“Additionally, real TBS resulted in reduced brain reactivity to alcohol cues, including decreased connectivity between the medial prefrontal cortex (MPFC) and the striatum and insula [110].”
BackgroundMotivational interviewing for substance use reduction
Schwenker, R., Dietrich, C. E., Hirpa, S., Nothacker, M., Smedslund, G., Frese, T., & Unverzagt, S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008063.pub3 · Cited by 56 · cited 1×
“MI demonstrated a standardized mean difference (SMD) of 0.48 compared to no intervention, indicating a small to moderate effect, while also showing potential improvements in treatment retention, with an SMD of 0.26 [118].”
MethodInfluentialDavidson, B., Giacobbe, P., George, T. P., Nestor, S. M., Rabin, J. S., Goubran, M., Nyman, A. J., Baskaran, A., Meng, Y., Pople, C. B., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01677-6 · Cited by 52
Propofol for Treatment of Refractory Alcohol Withdrawal Syndrome: A Review of the Literature
Brotherton, A. L., Hamilton, E. P., Kloss, H. G., & Hammond, D. A. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1726 · Cited by 51 · cited 1×
“A comprehensive review [26] concluded that propofol for AWS yields mixed results, with propofol being comparable to benzodiazepine monotherapy for severe alcohol withdrawal.”
BackgroundPilar, M. R., Eyler, A. A., Moreland‐Russell, S., & Brownson, R. C. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00279 · Cited by 51
Krupitsky, E. M., Grineko, A. Y., Berkaliev, T. N., Paley, A. I., Tetrov, U. N., Mushkov, K. A., & Borodikin, Y. S. (1992) · Alcoholism Treatment Quarterly · doi:10.1300/j020v09n01_09 · Cited by 49
Bogenschutz, M. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990002 · Cited by 47 · cited 1×
“Scientists were exploring whether its ability to enhance self-awareness could be beneficial in therapy for individuals with a history of alcohol misuse [74].”
BackgroundMo, Y., Thomas, M. C., & Karras, G. E. (2016) · Journal of Critical Care · doi:10.1016/j.jcrc.2015.11.022 · Cited by 47 · cited 1×
“It can be used as monotherapy or in conjunction with benzodiazepines where benzodiazepines fail or refractory DTs are a concern [19].”
BackgroundFarokhnia, M., Browning, B. D., Crozier, M. E., Sun, H., Akhlaghi, F., & Leggio, L. (2022) · Addiction Biology · doi:10.1111/adb.13211 · Cited by 46 · cited 1×
“Exploratory analyses revealed correlations between GLP-1R gene expression levels and behavioral measures of alcohol consumption [98].”
BackgroundShah, P., McDowell, M., Ebisu, R., Hanif, T., & Toerne, T. (2018) · Journal of Medical Toxicology · doi:10.1007/s13181-018-0662-8 · Cited by 46 · cited 1×
“There were no documented central nervous system adverse effects [25].”
BackgroundThe Neuroimmune Basis of Excessive Alcohol Consumption
Mayfield, J., & Harris, R. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.177 · Cited by 45
Using contingency management procedures to reduce at-risk drinking in heavy drinkers
Dougherty, D. M., Lake, S. L., Hill-Kapturczak, N., Liang, Y., Karns, T. E., Mullen, J., & Roache, J. D. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12687 · Cited by 45 · cited 1×
“Furthermore, these reductions persisted or became more pronounced during the follow up phase [121].”
BackgroundTolonen, J., Rossinen, J., Alho, H., & Harjola, V.-P. (2013) · European Journal of Emergency Medicine · doi:10.1097/mej.0b013e32835c53b3 · Cited by 45 · cited 1×
“In the study, the use of dexmedetomidine as a second-line medication for severe alcohol withdrawal delirium, following local sedation protocol, prevented the need for anesthesia and intubation in all subjects [37].”
BackgroundAdjunct Ketamine Use in the Management of Severe Ethanol Withdrawal
Pizon, A. F., Lynch, M. J., Benedict, N. J., Yanta, J. H., Frisch, A., Menke, N. B., Swartzentruber, G. S., King, A. M., Abesamis, M. G., & Kane-Gill, S. L. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003204 · Cited by 45 · cited 1×
“In a retrospective study involving 63 patients admitted to the ICU and diagnosed with DTs, those treated with symptom-triggered benzodiazepines, phenobarbital, plus IV ketamine had a significantly lower intubation rate and spent fewer days in the ICU [24].”
BackgroundEnhancement of alcohol withdrawal convulsions in mice by haloperidol
Blum, K., Eubanks, J. D., Wallace, J. E., & Hamilton, H. (1976) · Clinical Toxicology · doi:10.3109/15563657608988141 · Cited by 44 · cited 1×
“The use of antipsychotics, specifically haloperidol, is recommended only in combination with benzodiazepines, particularly in ICU and for patients experiencing DTs or those with comorbid psychotic disorders [42,43].”
BackgroundKamboj, S. K., Irez, D., Serfaty, S., Thomas, E., Das, R. K., & Freeman, T. P. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx064 · Cited by 41 · cited 1×
“The mindfulness group exhibited a significant reduction in past-week alcohol consumption at the 7-day follow-up, while the relaxation group did not show a significant change [127].”
BackgroundPotential of GABAB Receptor Positive Allosteric Modulators in the Treatment of Alcohol Use Disorder
Maccioni, P., & Colombo, G. (2019) · CNS Drugs · doi:10.1007/s40263-018-0596-3 · Cited by 40 · cited 1×
“ASP8062 is a novel agent which acts as a positive allosteric modulator of GABA-B, similar to baclofen, which is an orthosteric GABA-B receptor agonist [58].”
BackgroundStievenard, A., Méquinion, M., Andrews, Z. B., Destée, A., Chartier-Harlin, M.-C., Viltart, O., & Vanbesien-Mailliot, C. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.021 · Cited by 39 · cited 1×
“Its interaction with neurobiological circuits, such as the cholinergic–dopaminergic pathway, hints at its possible role in drug-seeking and addictive behaviors [90].”
BackgroundNaltrexone: A History and Future Directions.
Srivastava, A. B., & Gold, M. S. (2018) · Cerebrum : the Dana forum on brain science · Cited by 39
Self-citationLSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice
Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00994 · Cited by 38 · cited 1×
“This reduction was sustained for 46 days after LSD administration, suggesting a biologically mediated effect beyond psychological factors [76].”
BackgroundKolp, E., Friedman, H. L., Young, M. S., & Krupitsky, E. (2006) · The Humanistic Psychologist · doi:10.1207/s15473333thp3404_7 · Cited by 38
Caputo, F., Skala, K., Mirijello, A., Ferrulli, A., Walter, H., Lesch, O., & Addolorato, G. (2014) · CNS Drugs · doi:10.1007/s40263-014-0183-1 · Cited by 34 · cited 1×
“Both GHB and oxazepam were well tolerated, and no severe side effects were reported [46].”
BackgroundMurai, N., Kondo, Y., Akuzawa, S., Mihara, T., Shiraishi, N., Kakimoto, S., & Matsumoto, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172750 · Cited by 34
Ibudilast for the treatment of drug addiction and other neurological conditions
Johnson, K. W., Matsuda, K., & Iwaki, Y. (2014) · Clinical Investigation · doi:10.4155/cli.14.8 · Cited by 29
Corrêa Filho, J. M., & Baltieri, D. A. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.12.018 · Cited by 26
Baclofen for alcohol withdrawal
Liu, J., & Wang, L.-N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008502.pub4 · Cited by 26
Grodin, E. N., Nieto, S. J., Meredith, L. R., Burnette, E., O'Neill, J., Alger, J., London, E. D., Miotto, K., Evans, C. J., Irwin, M. R., et al. (2022) · Addiction Biology · doi:10.1111/adb.13182 · Cited by 25 · cited 1×
“Interestingly, a link was observed between C-reactive protein and choline compound (Cho) levels, and Cho levels in the brain predicted drinking behavior in the following week [87].”
BackgroundBaclofen and the Alcohol Withdrawal Syndrome—A Short Review
Cooney, G., Heydtmann, M., & Smith, I. D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00773 · Cited by 24 · cited 1×
“This process establishes a negative feedback loop, ultimately resulting in a decrease in excitatory neurotransmitters, a parallel to the effects of alcohol [14].”
BackgroundWoods, A. D., Giometti, R., & Weeks, S. M. (2015) · JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2015-1602 · Cited by 23
Mattle, A. G., McGrath, P., Sanu, A., Kunadharaju, R., Kersten, B., Zammit, K., & Mammen, M. J. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109671 · Cited by 21 · cited 1×
“Subgroup analyses, particularly for severe AWS patients, indicated a significant decrease in hospital length of stay and a reduction in benzodiazepine administration in gabapentin-treated patients [30].”
BackgroundGuiraud, J., Addolorato, G., Aubin, H.-J., Batel, P., de Bejczy, A., Caputo, F., Goudriaan, A. E., Gual, A., Lesch, O., Maremmani, I., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.003 · Cited by 20 · cited 1×
“The study reported no safety concerns [61].”
Kenna, G. A., Zywiak, W. H., Swift, R. M., McGeary, J. E., Clifford, J. S., Shoaff, J. R., Fricchione, S., Brickley, M., Beaucage, K., Haass-Koffler, C. L., et al. (2014) · Alcohol · doi:10.1016/j.alcohol.2014.04.005 · Cited by 20 · cited 1×
“The study revealed that a genetic variation in the serotonin 5-HT3 transporter (5-HTTLRP) influenced the effectiveness of ondansetron therapy, demonstrating a direct link between genetic polymorphism and the response to pharmacological treatment [70].”
BackgroundAddressing anger, stress, and alcohol-related difficulties in the military: An ACT intervention
Harvey, S. T., Henricksen, A., Bimler, D., & Dickson, D. (2017) · Military Psychology · doi:10.1037/mil0000173 · Cited by 20 · cited 1×
“The intervention group exhibited improvements, including reduced alcohol consumption, anxiety, and stress [126].”
BackgroundA Bayesian meta-analysis of topiramate’s effectiveness for individuals with alcohol use disorder
Fluyau, D., Kailasam, V. K., & Pierre, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221149643 · Cited by 20 · cited 1×
“Notably, topiramate was associated with a significantly higher prevalence of paresthesia, drowsiness, and memory impairment compared to the placebo [65].”
BackgroundWalzer, M., Marek, G. J., Wu, R., Nagata, M., & Han, D. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.766 · Cited by 19
Leighty, A. E., & Ansara, E. D. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.11.392 · Cited by 19
Love, K., & Zimmermann, A. E. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1539 · Cited by 14 · cited 1×
“In a recent retrospective study [27] on severe AWS in the ICU, the combination of propofol and dexmedetomidine demonstrated a higher reduction in CIWA-Ar scores within 24 h compared to their individual use.”
BackgroundPourmand, A., AlRemeithi, R., Kartiko, S., Bronstein, D., & Tran, Q. K. (2023) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2023.04.002 · Cited by 13
Comparison between baclofen and topiramate in alcohol dependence: A prospective study
Kapoor, A., Jose, N., Yadav, P., & Mahla, V. (2019) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_57_19 · Cited by 12 · cited 1×
“[64].”
The effect of neuroimmune modulation on subjective response to alcohol in the natural environment
Meredith, L. R., Grodin, E. N., Montoya, A. K., Miranda, R., Squeglia, L. M., Towns, B., Evans, C., & Ray, L. A. (2022) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14821 · Cited by 12
Alcoholics Anonymous and other 12-step programs for alcohol use disorder
Kelly, J. F., Humphreys, K. N., & Ferri, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012880 · Cited by 10
DeFoster, R. E., Morgan, R. J., Leung, J. G., Schenzel, H., Vijapura, P., Kashiwagi, D. T., Fischer, K. M., Philbrick, K. L., & Kung, S. (2023) · Substance Use & Misuse · doi:10.1080/10826084.2023.2236223 · Cited by 5 · cited 1×
“Secondary measures, including seizures, DTs, ICU transfer, and patient-reported symptoms, showed no statistical differences be-tween the two groups [29].”
BackgroundCrunelle, C. L., Jegham, S., Vanderbruggen, N., & Matthys, F. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad050 · Cited by 5
Filewod, N. C. J., Hwang, S. W., Turner, C. J., Rizvi, L., Gray, S. H., Klaiman, M., Buell, D., Ailon, J., Caudarella, A., Ginocchio, G. F., et al. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-021-00963-4 · Cited by 4
Faustmann, T. J., Paschali, M., Kojda, G., Schilbach, L., & Kamp, D. (2025) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2029-6387 · Cited by 4 · cited 1×
“The use of antipsychotics, specifically haloperidol, is recommended only in combination with benzodiazepines, particularly in ICU and for patients experiencing DTs or those with comorbid psychotic disorders [42,43].”
BackgroundKarapetyan, K. (2023) · Federal Practitioner · doi:10.12788/fp.0362 · Cited by 3 · cited 1×
“In another study comparing the length of stay of patients with AWS between the gabapentin/baclofen combination and lorazepam, the mean length of stay in the gabapentin/ baclofen group was significantly shorter compared with the benzodiazepine group [17].”
BackgroundENĂTESCU, V. R. (2020) · FARMACIA · doi:10.31925/farmacia.2020.6.14 · Cited by 2
Research works printed but not linked: 2
- Suddock J.T. Cain M.D. Barbiturate Toxicity StatPearls Publishing Treasure Island, FL, USA 2022 29763050
- Kabat-Zinn J. Full Catastrophe Living, Revised Edition: How to Cope with Stress, Pain and Illness Using Mindfulness Meditation Hachette London, UK 2013
Cited by
Cuproptosis: unveiling a new frontier in cancer biology and therapeutics
Feng, Y., Yang, Z., Wang, J., & Hai, Z. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01625-7 · Cited by 98
Alcohol in Daily Products: Health Risks, Cultural Considerations, and Economic Impacts
Herdiana, Y. (2025) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s495493 · Cited by 36
Reiter, N., Otte, H. R., Dalhoff, K., Wamberg, C., Petersen, T. S., & Meyhoff, C. S. (2025) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.70046 · Cited by 8
Reiter, N., Dalhoff, K., Petersen, T. S., Andersen, C. U., Wamberg, C., Erikstrup Clausen, N., Itenov, T. S., & Meyhoff, C. S. (2026) · Clinical Toxicology · doi:10.1080/15563650.2026.2630024 · Cited by 5
Epigenetic Insights into Substance Use Disorder and Associated Psychiatric Conditions
Ngo, A. L., Ahmad, C. M., Alkhansari, N. G., Nguyen, L., & Zhang, H. (2025) · Complex Psychiatry · doi:10.1159/000544912 · Cited by 8
Metadata
- Authors
- Celik, M., Gold, M. S., & Fuehrlein, B.
- Affiliations
- New York Medical College (US)
- Washington University in St. Louis (US)
- Yale University (US)
- Corresponding author
- Gold, Mark S.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2024-03-20
- Volume
- 14
- Issue
- 3
- Pages
- 294
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC10969323
- OpenAlex
- W4392986055
- Cited by
- 25
- References
- 135
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 5
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- alcoholism, alcohol withdrawal, pharmacotherapy, psychedelics, psychotherapy, phosphodiesterase-4 inhibitors, GLP-1 receptor agonists, treatment gap, disease burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
